The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $3.24

Today's change-0.20 -5.69%
Updated July 26 3:26 PM EDT. Delayed by at least 15 minutes.
 

Orexigen Therapeutics Inc

Nasdaq: OREX
Last

(U.S.) $3.24

Today's change-0.20 -5.69%
Updated July 26 3:26 PM EDT. Delayed by at least 15 minutes.

Orexigen Therapeutics Inc down (U.S.)$0.20

Orexigen Therapeutics Inc is sharply lower today, dropping (U.S.)$0.20 or 5.69% to (U.S.)$3.24. Over the last five days, shares have lost 12.57% and are down 81.19% for the last year to date. This security has underperformed the S&P 500 by 96.49% during the last year.

Key company metrics

  • Open(U.S.) $3.43
  • Previous close(U.S.) $3.43
  • High(U.S.) $3.50
  • Low(U.S.) $3.22
  • Bid / Ask(U.S.) $3.23 / (U.S.) $3.24
  • YTD % change-81.19%
  • Volume144,243
  • Average volume (10-day)286,923
  • Average volume (1-month)227,366
  • Average volume (3-month)239,815
  • 52-week range(U.S.) $3.22 to (U.S.) $46.40
  • Beta2.04
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.41
Updated July 26 3:26 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-293.65%

Although this company's net profit margin is negative, it is above the industry average and implies that Orexigen Therapeutics Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.32%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue55105
Total other revenue--------
Total revenue55105
Gross profit--------
Total cost of revenue--------
Total operating expense28182126
Selling / general / administrative17121211
Research & development126915
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-23-13-11-21
Interest income (expense), net non-operating-2-2-2-2
Gain (loss) on sale of assets--------
Other--------
Income before tax-22-16-11-23
Income after tax-22-18-11-23
Income tax, total--1----
Net income-22-18-11-23
Total adjustments to net income--------
Net income before extra. items-22-18-11-23
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-22-18-11-23
Inc. avail. to common incl. extra. items-22-18-11-23
Diluted net income-22-18-11-23
Dilution adjustment--------
Diluted weighted average shares15151313
Diluted EPS excluding extraordinary itemsvalue per share-1.54-1.22-0.86-1.80
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-1.54-1.22-0.86-1.80